Pediatric use of carbapenems;Utilisation des carbapénèmes en pédiatrie

Archives de Pediatrie

Volumn 17, Issue SUPPL. 4, 2010, Pages

  Durrmeyer, X ^a   Cohen, R ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

Bact ries multir sitantes; Carbap n me; Infections bact riennes

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CILASTATIN PLUS IMIPENEM; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; CHILD; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERANCE; DRUG UTILIZATION; GRAM NEGATIVE INFECTION; HUMAN; NONHUMAN; PEDIATRICS; PHARMACODYNAMICS;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CARBAPENEMS; CHILD; DRUG TOLERANCE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; THIENAMYCINS;

EID: 77956333848     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(10)70919-2     Document Type: Article

References (46)

1. Foglia E.E., Fraser V.J., Elward A.M. Effect of nosocomial infections due to antibiotic-resistant organisms on length of stay and mortality in the pediatric intensive care unit. Infect Control Hosp Epidemiol 2007, 28:299-306.
2. Norrby S.R. Carbapenems. Med Clin North Am 1995, 79:745-759.
3. Daikos G.L., Petrikkos P., Psichogiou M., et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009, 53:1868-1873.
4. Livermore D.M., Sefton A.M., Scott G.M. Properties and potential of ertapenem. J Antimicrob Chemother 2003, 52:331-344.
5. Paterson D.L., Depestel D.D. Doripenem. Clin Infect Dis 2009, 49:291-298.
6. Edwards J.R., Turner P.J. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis Suppl 1995, 96:5-10.
7. Sunagawa M., Matsumura H., Inoue T., et al. A novel carbapenem antibiotic, SM-7338 structure-activity relationships. J Antibiot (Tokyo) 1990, 43:519-532.
8. Overturf G.D. Carbapenemases: a brief review for pediatric infectious disease specialists. Pediatr Infect Dis J 2010, 29:68-70.
9. Fritsche T.R., Sader H.S., Toleman M.A., et al. Emerging metallo-beta-lactamase-mediated resistances: a summary report from the worldwide SENTRY antimicrobial surveillance program. Clin Infect Dis 2005, 41(Suppl 4):S276-S278.
10. El Amin N., Giske C.G., Jalal S., et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 2005, 113:187-196.
11. Cohen R. Apport de la pharmacocinetique-pharmacodynamie au traitement des infections bacteriennes de l'enfant. Arch Pediatr 2008, 15(Suppl 2):S53-S58.
12. MacGowan A.P., Bowker K.E. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998, 35:391-402.
13. Jaruratanasirikul S., Sriwiriyajan S., Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005, 49:1337-1339.
14. van den Anker J.N., Pokorna P., Kinzig-Schippers M., et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother 2009, 53:3871-3879.
15. Courter J.D., Kuti J.L., Girotto J.E., et al. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009, 53:379-385.
16. Zhanel G.G., Wiebe R., Dilay L., et al. Comparative review of the carbapenems. Drugs 2007, 67:1027-1052.
17. Zanetti G., Bally F., Greub G., et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003, 47:3442-3447.
18. Fitoussi F., Doit C., Benali K., et al. Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis. Antimicrob Agents Chemother 1998, 42:942-944.
19. Wong V.K., Wright H.T., Ross L.A., et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991, 10:122-125.
20. Klugman K.P., Dagan R. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Antimicrob Agents Chemother 1995, 39:1140-1146.
21. Odio C.M., Puig J.R., Feris J.M., et al. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999, 18:581-590.
22. Asensi V., Carton J.A., Maradona J.A., et al. Imipenem therapy of brain abscesses. Eur J Clin Microbiol Infect Dis 1996, 15:653-657.
23. Principi N., Marchisio P. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group. J Chemother 1998, 10:108-113.
24. Schuler D. Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. Meropenem Paediatric Study Group. J Antimicrob Chemother 1995, 36(Suppl A):99-108.
25. Byrne S., Maddison J., Connor P., et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother 1995, 36(Suppl A):135-143.
26. Blumer J.L., Saiman L., Konstan M.W., et al. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005, 128:2336-2346.
27. Latzin P., Fehling M., Bauernfeind A., et al. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros 2008, 7:142-146.
28. Yildirim I., Aytac S., Ceyhan M., et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in childhood hematological malignancies. Pediatr Hematol Oncol 2008, 25:291-299.
29. Duzova A., Kutluk T., Kanra G., et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 2001, 43:105-109.
30. Agaoglu L., Devecioglu O., Anak S., et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001, 13:281-287.
31. Oguz A., Karadeniz C., Citak E.C., et al. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors. Pediatr Hematol Oncol 2006, 23:245-253.
32. Hung K.C., Chiu H.H., Tseng Y.C., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect 2003, 36:254-259.
33. Fleischhack G., Hartmann C., Simon A., et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. J Antimicrob Chemother 2001, 47:841-853.
34. Riikonen P. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J 1991, 10:918-923.
35. Laszlo D., Bacci S., Bosi A., et al. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients. J Chemother 1997, 9:95-101.
36. Freifeld A.G., Walsh T., Marshall D., et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995, 13:165-176.
37. Uhari M., Seppanen J., Heikkinen E. Imipenem-cilastatin vs. tobramycin and metronidazole for appendicitis-related infections. Pediatr Infect Dis J 1992, 11:445-450.
38. Ahonkhai V.I., Cyhan G.M., Wilson S.E., et al. Imipenem-cilastatin in pediatric patients: an overview of safety and efficacy in studies conducted in the United States. Pediatr Infect Dis J 1989, 8:740-744.
39. Velaphi S., Wadula J., Nakwa F. Mortality rate in neonates infected with extended-spectrum beta lactamase-producing Klebsiella species and selective empirical use of meropenem. Ann Trop Paediatr 2009, 29:101-110.
40. Hsu H.L., Lu C.Y., Tseng H.Y., et al. Empirical monotherapy with meropenem in serious bacterial infections in children. J Microbiol Immunol Infect 2001, 34:275-280.
41. Koksal N., Hacimustafaoglu M., Bagci S., et al. Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria. Indian J Pediatr 2001, 68:15-19.
42. Nalin D.R., Jacobsen C.A. Imipenem/cilastatin therapy for serious infections in neonates and infants. Scand J Infect Dis Suppl 1987, 52:46-55.
43. Bradley J.S., Dudley M.N., Drusano G.L. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 2003, 22:982-992. quiz 993-5.
44. Bradley J.S., Sauberan J.B., Ambrose P.G., et al. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J 2008, 27:794-799.
45. Boswald M., Dobig C., Kandler C., et al. Pharmacokinetic and clinical evaluation of serious infections in premature and new-born infants under therapy with imipenem/cilastatin. Infection 1999, 27:299-304.
46. Reed M.D., Kliegman R.M., Yamashita T.S., et al. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother 1990, 34:1172-1177.